The company reported a weak third quarter, with earnings below estimates.
PI Industries reported a net profit of ₹311 crore, down 16% from the previous year’s ₹373 crore. The Street had estimated a 17% decline in net profit.
Its revenue declined 28% to ₹1,376 crore from ₹1,901 crore in the previous year. This was also not in-line with estimates of a 15% revenue decline.
Its earnings before interest, tax, depreciation and amortisation (EBITDA) declined 41% to ₹302 crore from ₹512 crore in the third quarter of the previous year. The Street had estimated a 19% decline in EBITDA.
PI Industries’ EBITDA margin contracted to 21.97%, declining 496 basis points from 16.94% in the year-ago period. The Street had estimated a 140 basis point contraction.
PI Industries reported an exceptional gain of ₹105 crore.
It reported a 126 crore one-time exceptional gain from write-back of excess earn-out provision post renegotiated settlement with erstwhile promoters of the acquired pharma business. It also reported a ₹21 crore new labour code impact.
In the December quarter, PI Industries reported a 32% decline in agrochem exports. Volumes were down 29%.
The company’s pharma revenue contracted by 6% from the previous year due to deferment of the supply schedules to the fourth quarter of FY26.
Shares of PI Industries declined 5.8% to hit an intraday low of ₹3,035 apiece. The stock later recovered from its day’s lows and was trading 1% lower at ₹3,192.5 apiece around 10 am. The stock has declined 15.3% in the past six months.
Also Read: Honasa Consumer gains 3% after solid Q3, but stock still trades below IPO price
First Published: Feb 13, 2026 10:04 AM IST